Tarlatamab

塔拉妥单抗

Report date: 2026/05/12 20:00:17
First In Class

Base Information

Drug NameTarlatamab
Drug Alias Nametarlatamab-dlleImdelltra安泰适AMG-757
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > T cell engagers
Mechanisms of ActionDelta-like protein 3 inhibitorsT-cell surface glycoprotein CD3 epsilon chain modulatorsImmunologic cytotoxicity +[4] 
TargetsDelta-like protein 3T-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Brain metastasesParanasal Sinus Diseases +[19] 
Global Approved IndicationsSmall Cell Lung Carcinoma
Approved Indications in ChinaSmall Cell Lung Carcinoma
Original Approved Country/TerritoryUnited States
Original Approved Date2024/05/16
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesMaastricht University Medical CenterRoyalty PharmaThe University Of Arizona +[7] 
Inactive CompaniesAmgen Biotechnology Consultation (Shanghai) Co Ltd
Active IndicationsMedullary thyroid cancer (MTC)Brain metastasesParanasal Sinus Diseases +[18] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG